GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a strategic partnership with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, in the development of its Eversense® Remote Patient Monitoring (RPM) Program for use by the health care providers..

医学技术公司Senseonics Holdings，Inc.（纽约证券交易所美国代码：SENS），专注于为糖尿病患者开发和制造长期植入式连续血糖监测（CGM）系统，今天宣布与Rimidi建立战略合作伙伴关系，Rimidi是一家领先的临床管理平台，旨在优化临床工作流程，增强患者体验，实现慢性病管理的质量目标，开发其Eversense®远程患者监测（RPM）计划供医疗保健提供者使用。。

“We are excited to combine our clinical management platform with Senseonics’ technology. Our platform and its capabilities were designed to leverage the data from medical devices like Eversense CGM to streamline and improve chronic disease management,” said Chief Executive Officer of Rimidi, Lucienne Ide, MD, PhD.

Rimidi首席执行官Lucienne Ide博士说：“我们很高兴将我们的临床管理平台与Senseonics的技术相结合。我们的平台及其功能旨在利用Eversense CGM等医疗设备的数据来简化和改进慢性病管理。”。

“81% of patients with type 2 diabetes do not meet their HbA1c, blood pressure and cholesterol goals, and this partnership represents an exciting opportunity to assist providers in driving improved glucose outcomes for this population.”.

“81%的2型糖尿病患者没有达到他们的HbA1c，血压和胆固醇目标，这种合作关系代表了一个令人兴奋的机会，可以帮助提供者改善这一人群的血糖结果。”。

The partnership will integrate Eversense glucose data into Rimidi's comprehensive clinical management platform used by health systems, capitated health plans and physician practices. Rimidi's platform aligns with Medicare’s reimbursable remote patient monitoring telehealth programs while seamlessly integrating within existing Electronic Health Record (EHR) systems, supporting quality improvement initiatives, driving workflow optimization, increasing patient engagement and providing clinical decision support..

该合作伙伴关系将Eversense血糖数据整合到Rimidi的综合临床管理平台中，该平台由卫生系统、人头健康计划和医生实践使用。Rimidi的平台与Medicare的可报销远程患者监测远程健康计划保持一致，同时无缝集成到现有的电子健康记录（EHR）系统中，支持质量改进计划，推动工作流程优化，提高患者参与度并提供临床决策支持。。

Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers. With increased visibility on glucose trends, high or low event frequency, and time-in-range statistics, providers will be able to proactively engage patients to provide lifestyle and therapy optimization guidance in order to better manage their diabetes, lower healthcare costs and improve clinical outcomes..

Eversense CGM+RPM解决方案由Rimidi提供支持，旨在无缝安全地将患者血糖数据推送到使用最广泛的EHR系统，为医疗保健提供者提供直接访问。随着对血糖趋势，高或低事件频率以及时间范围统计数据的可见性的提高，提供者将能够主动让患者提供生活方式和治疗优化指导，以更好地管理他们的糖尿病，降低医疗成本并改善临床结果。。

“The Eversense RPM Program™ is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution. Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.

Senseonics总裁兼首席执行官Tim Goodnow博士说：“Eversense RPM Program™是我们路线图的下一步，它将长期植入式CGM技术与先进的分析和个性化健康服务相结合，形成一个全面的糖尿病解决方案。Eversense RPM将为供应商提供强大的数据，以优化99%糖尿病管理发生的办公室就诊期间的护理。”。

“Rimidi’s best-in-class platform will seamlessly integrate Eversense data. Combined with expert diabetes nurse counselors, proprietary decision support protocols, and fully compliant RPM reimbursement infrastructure, our Eversense CGM+RPM solution is intended to further differentiate Eversense from other CGM manufacturers, reaching beyond a stand-alone device and putting a comprehensive solution into the hands of health care systems, providers, and patients.

“Rimidi一流的平台将无缝集成Eversense数据。结合专家糖尿病护理顾问、专有决策支持协议和完全符合RPM报销基础设施，我们的Eversense CGM+RPM解决方案旨在进一步区分Eversense与其他CGM制造商，超越单机设备，将全面解决方案交给医疗保健系统、提供商和患者。

Aligned with Medicare’s diabetes population management initiatives, we are proud to be at the forefront of providing the next evolution of innovation in diabetes with the goal to give healthcare professionals the confidence of knowing patients have support outside of their office and patients the confidence of achieving healthy outcomes.

与Medicare的糖尿病人口管理计划相一致，我们很自豪能够站在糖尿病创新的最前沿，目标是让医疗保健专业人员有信心知道患者在办公室之外有支持，让患者有信心实现健康的结果。

We look forward to providing Ascensia, our commercial partner, with this exciting program, offering further reason for providers and patients to choose Eversense.”.

我们期待着为我们的商业合作伙伴Ascensia提供这个令人兴奋的计划，为提供者和患者选择Eversense提供更多的理由。”。

Senseonics, in collaboration with its commercial partner, Ascensia Diabetes Care, intends to make the Eversense CGM+RPM solution available to select population health-based systems beginning in the third quarter of 2024, followed by a planned expansion of the program to all healthcare prescribers and users of Eversense..

Senseonics与其商业合作伙伴Ascensia Diabetes Care合作，打算从2024年第三季度开始，将Eversense CGM+RPM解决方案用于选择基于人群健康的系统，然后计划将该计划扩展到Eversense的所有医疗处方者和用户。。

Potential Eversense users can go to www.ascensiadiabetes.com/eversense to learn more about Eversense. Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/. Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system..

Eversense的潜在用户可以访问www.ascinsiadiabetes.com/Eversense了解更多有关Eversense的信息。有兴趣提供Eversense CGM系统的医生、护士和医生助理可以在https://www.ascensiadiabetes.com/eversense/become-a-provider/.或者，请联系1-844-SENSE4U（1-844-736-7348），以了解有关第一个也是唯一一个长期植入式CGM系统的更多信息。。

† There is no glucose data generated when the transmitter is removed

†拆除变送器时不产生葡萄糖数据

1 Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023;66(1):3-22.

1 Sherr JL，Heinemann L，Fleming GA等人。自动胰岛素输送：益处，挑战和建议。欧洲糖尿病研究协会和美国糖尿病协会联合糖尿病技术工作组的共识报告。糖尿病。2023年；66（1）：3-22。

doi:10.1007/s00125-022-05744-z.

doi:10.1007/s00125-022-05744-z。

2 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

2 Garg S.等人。下一代长达180天的长期植入式Eversense连续血糖监测系统的准确性和安全性评估：PROMISE研究。糖尿病技术与治疗2021；24（2）：1-9.DOI:10.1089/dia.2021.0182

3 Barnard KD, Kropff J, Choudhary P, et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. J Diabetes Sci Technol. 2018;12(3):634-638. doi:10.1177/1932296817735123

3 Barnard KD，Kropff J，Choudhary P等。植入式连续血糖监测传感器的可接受性。糖尿病科学技术杂志。2018年；12（3）：634-638。内政部：10.1177/1932296817735123

4 Boscari F, Vettoretti M, Cavallin F, et al. Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance. J Endocrinol Invest. 2022;45(1):115-124. doi:10.1007/s40618-021-01624-2

4 Boscari F，Vettoretti M，Cavallin F等。植入式和经皮连续血糖监测系统：一项比较准确性，有效性和可接受性的随机交叉试验。J内分泌投资。2022年；45（1）：115-124。内政部：10.1007/s40618-021-01624-2

5 Hanson K, Kipnes M, Tran H. Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems. J Diabetes Sci Technol. Published online January 8, 2024. doi:10.1177/19322968231225676

5 Hanson K，Kipnes M，Tran H.两种广泛使用的连续血糖监测系统之间点精度的比较。糖尿病科学技术杂志。2024年1月8日在线发布。内政部：10.1177/19322968231225676

6 Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technol Ther. 2018;20(3):197-206. doi:10.1089/dia.2017.0142

6 Christiansen MP，Klaff LJ，Bragg R等。新型植入式连续葡萄糖传感器准确性的前瞻性多中心评估：PRECISE II。糖尿病技术。2018年；20（3）：197-206。内政部：10.1089/dia.2017.0142

7 Eversense E3 User Manual LBL-4002-01-001 Rev B 02/2022

7 Eversense E3用户手册LBL-4002-01-001版本B 02/2022

About Eversense

关于Eversense

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class.

Eversense®E3连续血糖监测（CGM）系统适用于连续测量18岁及以上糖尿病患者长达180天的血糖水平。该系统用于替代用于糖尿病治疗决策的手指血糖（BG）测量。在第21天之后，当症状与CGM信息不匹配或服用四环素类药物时，仍然需要手指棒BG测量来进行校准，主要是每天一次。

The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/..

传感器的插入和拆卸程序由医疗保健提供者执行。Eversense E3 CGM系统是一种处方设备；患者应该与他们的医疗保健提供者交谈以了解更多信息。有关重要的安全信息，请参阅https://www.ascensiadiabetes.com/eversense/safety-info/..

About Senseonics

关于Senseonics

Senseonics Holdings, Inc. ('Senseonics') is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Holdings，Inc.（“Senseonics”）是一家医疗技术公司，专注于开发和制造血糖监测产品，旨在通过差异化的长期植入式血糖管理技术改变全球糖尿病社区的生活。Senseonics的CGM系统Eversense®E3包括一个完全插入皮肤下的小型传感器，该传感器与传感器上佩戴的智能变送器通信。

The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone..

葡萄糖数据每5分钟自动发送到用户智能手机上的移动应用程序。。

About Rimidi

关于Rimidi

Created by doctors, for doctors, Rimidi is a digital health company that supports healthcare providers in the delivery of remote patient monitoring and chronic disease management with EHR-integrated software, services, and connected devices. By combining clinical data from the EHR with data from connected devices and patient surveys, Rimidi presents a complete picture of the patient and supports care delivery across the continuum from the clinic to the home to allow for proactive, guideline-based management and prioritization of highest-need patients.

Rimidi是一家由医生为医生创建的数字健康公司，它通过EHR集成软件、服务和连接设备支持医疗保健提供商提供远程患者监测和慢性病管理。通过将EHR的临床数据与连接设备和患者调查的数据相结合，Rimidi提供了患者的完整图片，并支持从诊所到家庭的整个连续过程中的护理服务，以便对最需要的患者进行积极的，基于指南的管理和优先排序。

For more information, visit rimidi.com and follow us on X, formerly known as Twitter, and LinkedIn..

有关更多信息，请访问rimidi.com并在X（以前称为Twitter）和LinkedIn上关注我们。。

Forward Looking Statements

前瞻性声明

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the patient and provider experience, statements regarding launch expectations of the Eversense RPM solution, statements regarding the benefits of pursuing a new strategic partnership with Rimidi, statements regarding the attributes and value to patients and providers of Eversense RPM, statements regarding the design and implementation of Eversense RPM, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中关于Senseonics未来期望、计划和前景的任何声明，包括关于患者和提供者体验的声明、关于Eversense RPM解决方案推出期望的声明、关于与Rimidi建立新战略合作伙伴关系的益处的声明、关于Eversense RPM对患者和提供者的属性和价值的声明、关于Eversense RPM设计和实施的声明，以及其他包含“相信”、“期望”、“打算”、“可能”、“项目”、“将”、“计划”和类似表述的声明，均构成1995年《私人证券诉讼改革法》含义内的前瞻性声明。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the commercial launch and commercial expansion of the Eversense product and a new RPM solution, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties inherent in the development of new technology, uncertainties inherent in finalizing integration and commercial terms with a new partner, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2023 and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof.

由于各种重要因素的影响，实际结果可能与此类前瞻性声明所显示的结果存在重大差异，包括：Eversense产品和新RPM解决方案的商业发布和商业扩展固有的不确定性，商业化责任向Ascensia糖尿病护理及其商业举措过渡固有的不确定性，新技术开发固有的不确定性，与新合作伙伴最终确定集成和商业条款固有的不确定性，以及截至2023年12月31日的Senseonics 10-K年度报告以及Senseonics在“风险因素”标题下向美国证券交易委员会提交的其他文件中详述的风险因素中列出的其他因素。此外，本报告中包括的前瞻性声明新闻稿代表Senseonics截至本协议日期的观点。

Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forwar.

Senseonics预计随后的事件和发展将导致Senseonics的观点发生变化。然而，虽然Senseonics可能会选择更新这些forwar。